Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping TKI to Assess Treatment-Free Remission in Pediatric CML-CP
NCT03817398Phase 2Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Nov 2019
- Primary completion
- Sep 2026
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial in chronic myeloid leukemia (CML), sponsored by Children's Oncology Group. Primary endpoints: Treatment-free remission at 2 years and Major molecular remission at 1 year. Started Nov 2019; status: active, not recruiting.
02
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03817398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817398.